AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ibrexafungerp 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5462 | 1207753-03-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Ibrexafungerp, a triterpenoid antifungal agent, inhibits glucan synthase, an enzyme involved in the formation of 1,3-beta-D-glucan, an essential component of the fungal cell wall. Ibrexafungerp has concentration-dependent fungicidal activity against Candida species as measured by time kill studies. Ibrexafungerp retains in vitro antifungal activity when tested at pH 4.5 (the normal vaginal pH).
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
| BA (Bioavailability) | 40 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | EIF2AK3,GRK2,PDK1,PDK2 | 4 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 1, 2021 | FDA | SCYNEXIS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J02AX07 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE ANTIMYCOTICS FOR SYSTEMIC USE Other antimycotics for systemic use |
| FDA CS | M0022020 | Triterpenes |
| FDA MoA | N0000020027 | Glucan Synthase Inhibitors |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| FDA EPC | N0000193966 | Triterpenoid Antifungal |
| CHEBI has role | CHEBI:35718 | antifungal agent |
| CHEBI has role | CHEBI:86327 | antifungal drug |
Related Drugs by ATC class:
J02AX Other antimycotics for systemic use 5 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Vulvovaginal candidiasis | indication | 72605008 | DOID:2272 |
| Candidiasis of vagina | indication | 72934000 | |
| Pregnancy, function | contraindication | 289908002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| EQ 150MG BASE | BREXAFEMME | GLAXOSMITHKLINE | N214900 | June 1, 2021 | RX | TABLET | ORAL | 8188085 | Aug. 28, 2030 | TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC) |
| EQ 150MG BASE | BREXAFEMME | GLAXOSMITHKLINE | N214900 | June 1, 2021 | RX | TABLET | ORAL | 10370406 | Jan. 19, 2035 | TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC) |
| EQ 150MG BASE | BREXAFEMME | GLAXOSMITHKLINE | N214900 | June 1, 2021 | RX | TABLET | ORAL | 11534433 | June 10, 2039 | REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES |
| EQ 150MG BASE | BREXAFEMME | GLAXOSMITHKLINE | N214900 | June 1, 2021 | RX | TABLET | ORAL | 11534433 | June 10, 2039 | TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC) |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| EQ 150MG BASE | BREXAFEMME | GLAXOSMITHKLINE | N214900 | June 1, 2021 | RX | TABLET | ORAL | June 1, 2026 | NEW CHEMICAL ENTITY |
| EQ 150MG BASE | BREXAFEMME | GLAXOSMITHKLINE | N214900 | June 1, 2021 | RX | TABLET | ORAL | June 1, 2031 | GENERATING ANTIBIOTIC INCENTIVES NOW |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-1,3-glucan synthase catalytic subunit 1 | Enzyme | INHIBITOR | IC50 | 8.35 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| 1,3-Beta-D-glucan-UDP glucosyltransferase | Enzyme | INHIBITOR | IC50 | 7.83 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| 1,3-Beta-D-glucan-UDP glucosyltransferase | Enzyme | INHIBITOR | IC50 | 8.97 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| D11544 | KEGG_DRUG |
| A92JFM5XNU | UNII |
| 1965291-08-0 | SECONDARY_CAS_RN |
| C5206403 | UMLSCUI |
| CHEBI:756995 | CHEBI |
| CHEMBL4297513 | ChEMBL_ID |
| 46871657 | PUBCHEM_CID |
| DB12471 | DRUGBANK_ID |
| CHEMBL4298168 | ChEMBL_ID |
| 10597 | INN_ID |
| C569338 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4040654 | VANDF |
| 347181 | MMSL |
| 39565 | MMSL |
| d09756 | MMSL |
| 018755 | NDDF |
| 018756 | NDDF |
| 2560213 | RXNORM |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| BREXAFEMME | HUMAN PRESCRIPTION DRUG LABEL | 1 | 75788-115 | TABLET, FILM COATED | 150 mg | ORAL | NDA | 33 sections |